Brookline Capital Acquisition Corp.
Status: Deal Closed
U=S+W/2
W=S@11.5
| IPO Proceeds, $M | $57.50M |
|---|---|
| IPO Date | Jan 29, 2021 |
| CEO | Dr. Samuel P. Wertheimer |
| Left Lead | Ladenburg Thalmann |
| IPO Cash in Trust | 101.0% |
| SPAC Tenor | 15 + 6 |
| IPO Sector |
Healthcare
Life sciences in the US and Europe |
| IPO Geography | US/Canada |
| Target Company | Apexigen, Inc. |
| Deal Announced | Mar 18, 2022 |
| Deal Size, $M | $287.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Jul 27, 2022 |
| Amendment Vote | Apr 26, 2022 |
| Closing Date | Jul 29, 2022 |
Formerly BCAC
APGN
APGNW
| Price | 2.52 |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Brookline Capital Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 34 filings and events
- 1 underwriters
- 2 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Dr. Samuel P. Wertheimer | 60 | CEO and Chairman |
| Scott A Katzmann | 64 | President and Director |
| Patrick A. Sturgeon | 44 | CFO |
| James N. Hauslein | 61 | Director |
| Elgar Peerschke | 64 | Director |
| Tito A. Serafini, PhD | 56 | Director |
| Edgar D. Jannotta Jr. | Advisor | |
| Franklin M. Berger, CFA | Advisor |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Ladenburg Thalmann | BR | 5,000,000 | units |
| 5,000,000 | units | ||
| Up-Front UW fee | 1.50 | % | |
| Deferred UW fee |
0.00 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.